SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : biotech fireworks
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Julius Wong6/12/2018 7:35:09 AM
1 Recommendation

Recommended By
Thehammer

  Read Replies (1) of 7424
 
Galmed to release mid-stage data on NASH candidate Aramchol this morning; shares up 60% premarket

Thinly traded micro cap Galmed Pharmaceuticals (NASDAQ: GLMD) is up 60% premarket on light volume ahead of its 8:00 am ET conference call to discuss topline results from its Phase 2b ARREST study assessing Aramchol (arachidyl amido cholanoic acid) in nonalcoholic steatohepatitis (NASH).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News